Innovations in Biomaterial Design Toward Successful RNA Interference Therapy for Cancer Treatment

Overview

Journal Adv Healthc Mater

Specialties Biomedical Engineering
Biotechnology

Date 2021 May 11

PMID 33973393

Citations 12

Authors

Deidra M Ward

Aaliyah B Shodeinde

Nicholas A Peppas

Affiliations

Soon will be listed here.

Abstract

Gene regulation using RNA interference (RNAi) therapy has been developed as one of the frontiers in cancer treatment. The ability to tailor the expression of genes by delivering synthetic oligonucleotides to tumor cells has transformed the way scientists think about treating cancer. However, its clinical application has been limited due to the need to deliver synthetic RNAi oligonucleotides efficiently and effectively to target cells. Advances in nanotechnology and biomaterials have begun to address the limitations to RNAi therapeutic delivery, increasing the likelihood of RNAi therapeutics for cancer treatment in clinical settings. Herein, innovations in the design of nanocarriers for the delivery of oligonucleotides for successful RNAi therapy are discussed.

Citing Articles

Research progress of novel anti-tumor drug formulations.

Liu Y, Guo Q, Shi Y, Cui M, Jing F Front Oncol. 2024; 14:1507958.

PMID: 39737395 PMC: 11683012. DOI: 10.3389/fonc.2024.1507958.

Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.

Subhan M, Torchilin V Bioengineering (Basel). 2024; 11(8).

PMID: 39199788 PMC: 11351222. DOI: 10.3390/bioengineering11080830.

Liposome-based RNAi delivery in honeybee for inhibiting parasite .

Qi Y, Wang C, Lang H, Wang Y, Wang X, Zheng H Synth Syst Biotechnol. 2024; 9(4):853-860.

PMID: 39139857 PMC: 11320372. DOI: 10.1016/j.synbio.2024.07.003.

Emerging Perspectives on Prime Editor Delivery to the Brain.

BenDavid E, Ramezanian S, Lu Y, Rousseau J, Schroeder A, Lavertu M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931430 PMC: 11206523. DOI: 10.3390/ph17060763.

Gel/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery.

Feng Y, Zhang Z, Tang W, Dai Y Exploration (Beijing). 2023; 3(5):20220173.

PMID: 37933278 PMC: 10582614. DOI: 10.1002/EXP.20220173.

References

Song Z, Liang X, Wang Y, Han H, Yang J, Fang X . Phenylboronic acid-functionalized polyamidoamine-mediated miR-34a delivery for the treatment of gastric cancer. Biomater Sci. 2019; 7(4):1632-1642. DOI: 10.1039/c8bm01385c. View

Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T . miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. Biosci Rep. 2015; 35(4). PMC: 4613672. DOI: 10.1042/BSR20150084. View

Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T . Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014; 194:228-37. DOI: 10.1016/j.jconrel.2014.09.005. View

Geusens B, Lambert J, De Smedt S, Buyens K, Sanders N, Van Gele M . Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release. 2008; 133(3):214-20. DOI: 10.1016/j.jconrel.2008.10.003. View

Du J, Li H, Wang J . Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine. Acc Chem Res. 2018; 51(11):2848-2856. DOI: 10.1021/acs.accounts.8b00195. View

Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla Z . Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 2008; 16(3):217-26. PMC: 3052284. DOI: 10.1038/cgt.2008.79. View

Ozpolat B, Sood A, Lopez-Berestein G . Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66:110-6. PMC: 4527165. DOI: 10.1016/j.addr.2013.12.008. View

Wasungu L, Hoekstra D . Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release. 2006; 116(2):255-64. DOI: 10.1016/j.jconrel.2006.06.024. View

Song C, Xiao Y, Ouyang Z, Shen M, Shi X . Efficient co-delivery of microRNA 21 inhibitor and doxorubicin to cancer cells using core-shell tecto dendrimers formed via supramolecular host-guest assembly. J Mater Chem B. 2020; 8(14):2768-2774. DOI: 10.1039/d0tb00346h. View

10.

Meade B, Dowdy S . Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev. 2007; 60(4-5):530-6. PMC: 2293332. DOI: 10.1016/j.addr.2007.10.004. View

11.

Tanaka T, Mangala L, Vivas-Mejia P, Nieves-Alicea R, Mann A, Mora E . Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010; 70(9):3687-96. PMC: 3202607. DOI: 10.1158/0008-5472.CAN-09-3931. View

12.

Van Asbeck A, Beyerle A, McNeill H, Bovee-Geurts P, Lindberg S, Verdurmen W . Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano. 2013; 7(5):3797-807. DOI: 10.1021/nn305754c. View

13.

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

14.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

15.

Lopez-Bertoni H, Lal B, Michelson N, Guerrero-Cazares H, Quinones-Hinojosa A, Li Y . Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Oncogene. 2016; 35(37):4903-13. PMC: 6151872. DOI: 10.1038/onc.2016.22. View

16.

Qian X, Ren Y, Shi Z, Long L, Pu P, Sheng J . Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm. 2012; 9(9):2636-45. DOI: 10.1021/mp3002039. View

17.

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

18.

Singh P, Hollingsworth M . Cell surface-associated mucins in signal transduction. Trends Cell Biol. 2006; 16(9):467-76. DOI: 10.1016/j.tcb.2006.07.006. View

19.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

20.

Campani V, Zappavigna S, Scotti L, Abate M, Porru M, Leonetti C . Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. Int J Pharm. 2020; 588:119693. DOI: 10.1016/j.ijpharm.2020.119693. View